What kept going up even in the depths of the worst recession since the 1930s? Health spending. It rose 4% in 2009 to an alltime record of 17.6% of gross domestic product. We are far above every other nation in health spending but don't have the longevity to show for it. Health costs are by far the biggest threat to the nation's fiscal health in the long run.

Investor Randal J. Kirk became very rich making small improvements to old drug classes. Now he and partner Thomas Reed want to change the world.

Instead of ignoring the placebo effect, doctors should try to enhance it, says a Harvard Medical School professor.

MONSANTO'S FIRST ROUND OF ATTACKERS SAID ITS SEEDS WERE EVIL. NOW THE CHARGE IS THAT MONSANTO'S SEEDS ARE TOO GOOD.

Only a precious few disease-screening tests make a difference in healthy adults. Here's what you need to know.

Does every cancer patient really need proton-beam therapy?

We're winning the war on heart attacks. But heart disease remains the number one killer. What works, what doesn't and what you need to know.

美国新兴的个人基因检测行业目前正面临考验.今年上半年,纽约州健康署向6家在线从事类似业务的公司发出了罚款和监禁的警告信.信中要求,未经许可,公司不能对纽约市民进行基因检测.

Stem cells are the fountain of youth- or the tools of SATAN. It depends on whom you ask. Somewhere in between are pioneering compaines making incredible strides in medicine.

威斯康辛州大学一位籍籍无名的生物学家第一次在实验室里培育出了人体胚胎干细胞后,关于这个领域的研究和争论日趋热门。

出于对在线基因检测结果可信度的质疑,及可能对民众产生误导的担忧,纽约州健康署向6家在线从事个人基因检测的公司发出了警告。

一项名为JUPITER的研究由阿斯利康公司赞助,该研究对18 000名CRP评分较低的患者给予Crestor(rosuvastatin calcium)或安慰剂进行对照观察治疗,CRP名为C反应蛋白,是近年来开始应用的一项评价动脉中炎症发生情况的指标.研究结果显示,与安慰剂组相比,Crestor用药组群发生心梗、中风、手术切开阻塞动脉的风险性只有50%,这也是他汀类药物问世20年来获得最佳结果的研究之一.

Your genes may know. Supercheap DNA scanning is set to jolt medicine, offering patients new insights- and painful choices.

Understanding how the body's tiny components communicate is opening up.